Sign in
Enrolling by invitationPhase 2/3

Continued Treatment With SKY-0515 for People With Huntington's Disease

Tests SKY-0515, taken by mouth, in adults with Huntington's disease from an earlier study.

Key facts

Who runs it
Skyhawk Therapeutics, Inc.
Where
Auckland, Christchurch, and Wellington, New ZealandSee the 3 sitesAlso in 1 other country, 7 sites
Trial code
Registry title
An Extension of SKY-0515 in Participants With Huntington's Disease
Status
Enrolling by invitation
Phase
Phase 2/3
People taking part
500 people, planned
Started
10 Apr 2026
Expected to end
Dec 2029
Type of study
Interventional
Treatments tested
  • SKY-0515
Record updated
24 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with Huntington's disease who finished an earlier SKY-0515 treatment study and followed its procedures. They take the oral drug SKY-0515 in this extension.

Age
25 years and older
Sex
Men and women can join.
Disease stage
Huntington's disease confirmed by genetic testing (as stated in the summary).
Earlier treatment
Must have finished treatment in an earlier SKY-0515 study and followed its procedures.
Biomarker or test result
Huntington's disease confirmed by genetic testing.

Main reasons for not taking part

  • Any other condition that the investigator or sponsor thinks makes joining unsuitable or could stop the person from completing the study.
  • Cannot tolerate blood draws.
  • Cannot or will not attend all scheduled visits and follow the study procedures.
  • Women who can have children without a negative pregnancy test or without two types of birth control.
  • Men who will not use birth control during the study and for 90 days after the last dose.

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Must have completed treatment in a prior SKY-0515 treatment study and, in the opinion of the Investigator, have been compliant with the prior SKY-0515 treatment protocol study procedures
  • Must be able and willing to meet all study requirements in the opinion of the Investigator including:
  • Participants must be able to tolerate blood draws
  • Willing and able to comply with all scheduled visits, treatment plans,laboratory tests and other study procedures
  • Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug
  • Men must agree to use birth control during the study and for 90 days after the last dose

Who cannot take part

  • -Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study

Where in New Zealand

Also in 1 other country, 7 sites

  • Huntington's Disease AssociationAuckland, New ZealandEnrolling by invitation
  • New Zealand Brain and Research InstituteChristchurch, New ZealandEnrolling by invitation
  • Wellington HospitalWellington, New ZealandEnrolling by invitation

About the trial

What the trial wants to find out

The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.

The group in the trial

  • 9mg doseTreatment being tested

    Drug: SKY-0515 Type: Small molecule Route of Administration: Oral Dosage Frequency: Once daily Duration: until study drug is approved or study is discontinued Use: Experimental

    Treatment: SKY-0515

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open Label Extension of SKY-0515 in Participants With Huntington's Disease Who Completed a Prior SKY-0515 Treatment Study
Plain-language title
Continued Treatment With SKY-0515 for People With Huntington's DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
24 July 2026